CRL Charles River Laboratories International, Inc. Common Stock
NYSE · Life Sciences Tools & Services · Visualizza su SEC EDGAR ↗ chiudi Ott 2, 2026 10-K/10-Q Ago 5, 2026
$290,19
· % dell'intervallo 52 sett.
· sopra il minimo
· al massimo
$146,20minimo 52 sett.
$303,31massimo 52 sett.
Capitalizzazione di Mercato (MRQ)
$13.85B
P/E (TTM)
-60.5
EPS (TTM)
$-4.80
Ricavi (TTM)
$4.00B
i tuoi badge
Intervallo 52 sett.
$146–$303
Rating Analisti
BUY
Prezzo Obiettivo
$305
P/E
-60.5
ROE
-7.7%
Margine di Profitto Netto
-6.0%
La tua barra dei badge è vuota — aggiungi una metrica a piacere in questa pagina.
CRL Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$290.19
Capitalizzazione di Mercato (MRQ)
$13.85B
P/E (TTM)
-60.5
EPS (TTM)
$-4.80
Ricavi (TTM)
$4.00B
ROE (TTM)
-7.7%
D/E Debito/Patrimonio (MRQ)
0.0
Intervallo 52 sett.
$146–$303
CRL Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
intervallo
barre
La granularità delle barre si adatta al periodo selezionato — passa il mouse sul grafico per vedere apertura/massimo/minimo/chiusura di una barra.
Informazioni su Charles River Laboratories International, Inc. Common Stock Panoramica della società da Wikipedia
Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides goods and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients.
Charles River Laboratories is a global provider of non-clinical drug development services, known for its role in toxicology studies, research animal models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration (FDA). The company has also been the subject of public scrutiny and regulatory attention over its use of research animals, including dogs, primates, and horseshoe crabs.
As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL.
History
Charles River was founded in 1947 by Henry Foster, a young veterinarian who purchased one thousand rat cages from a Virginia farm and set up a one-person laboratory in Boston overlooking the Charles River. He supplied local researchers with laboratory animals.
In 1955, the company's headquarters were relocated to their current home in Wilmington, Massachusetts. The organization became an international entity in 1966 by opening a new animal production facility in France.
The first commercial, comprehensive genetic monitoring program was implemented by Charles River in 1981. Three years later, they were acquired by Bausch & Lomb. In 1988, the organization began creating transgenic mice and rats. In the 1990s, they began in vitro endotoxin testing. In the 1990s, Jim Foster bought Charles River back from Bausch & Lomb, and the company later went public on the New York Stock Exchange.
Charles River launched the Humane Care Imperative in 2002, designed to raise awareness and train employees on animal welfare's importance. The same year, they were named "Company of the Year" by The Boston Globe. The company introduced preconditioning services in 2005 to provide customers with study-ready animals.
In 2008, Charles River signed a ten-year contract to partner with the National Cancer Institute and opened a facility in Frederick, Maryland.
In April 2019, Charles River announced it would cease its San Diego operations, moving the breeding of rodents for testing compounds to Hollister, California.
In March 2023, the Born Free USA animal welfare organization protested against Charles River's plan to export 1,000 endangered juvenile long-tail macaques to Cambodia for testing.
Acquisitions
In 1988, Charles River purchased Specific Pathogen Antigen Free Avian Services (SPAFAS) and serologic diagnostic services Merck, Sharp, and Dohme.
Between 1996 and 2000, the company acquired Endosafe, Inc. and Sierra Biomedical.
In October 2003, Charles River Laboratories merged with Inveresk, a research company based in the United Kingdom. The company was known then as Charles River Laboratories. Inveresk specialised in clinical research and pre-clinical testing, and their main facilities are in Edinburgh, Scotland. In late 2009, Charles River sold its Clinical Services Division in Edinburgh to Quotient Bioresearch.
In 2010, Charles River Laboratories attempted to acquire WuXi PharmaTech, a China-based contract research organization, but the offer was withdrawn when the deal faced opposition from several large Charles River investors, including Relational Investors, JANA Partners, and Neuberger Berman. The proxy advisory firm RiskMetrics had also recommended that Charles River's shareholders vote against the proposed deal.
From 2008 to 2013, Charles River acquires several companies including NewLab Bioquality AG, MIR Preclinical Services, Piedmont Research Center, LLC, Cerebricon, Ltd., Accugenix, and Vital River, allowing the company to expand their research models and services portfolio to drug development and discovery markets in China.
The acquisitions of Argenta and BioFocus in 2014 allowed Charles River to establish itself as a full-service, early-stage contract research organization with integrated in vitro and in vivo capabilities from target discovery through pre-clinical development.
In July 2015, the company announced it would acquire Celsis International for $212 million.
In 2016, the company announced it was set to acquire WIL Research for approximately $585 million in cash and Blue Stream Laboratories.
In August 2017, the business announced it would acquire Brains On-Line.
In January 2018, the company announced it would acquire KWS BioTest for up to £18 million ($24.4 million). In February of the same year, Charles River announced it would acquire MPI Research for approximately $800 million in cash. The transaction was completed on April 3, 2018.
In February 2019, the company announced it would acquire Citoxlab for €448 million in cash (approximately $500 million), including the former acquisitions of the French company, AccelLAB, Atlanbio and Solvo Biotechnology. The transaction was completed on April 29. In December of the same year the business announced it would acquire HemaCare for approximately $380 million in cash.
In August 2020, the company announced it would acquire Cellero for $38 million in cash.
In January 2021, the company announced it would acquire Distributed Bio, Inc., an antibody discovery business.
In February 2021, Charles River announced it would acquire Cognate BioServices, Inc. for $875 million.
In March 2021, Charles River announced the acquisition of Retrogenix for $48 million.
In May 2021, Charles River announced the acquisition of Vigene Biosciences, a gene therapy contract development and manufacturing organization (CDMO), for $292.5 million.
In October 2021, a Japanese subsidiary of Charles River was acquired by Jackson Laboratory for $63M.
In April 2022, the company announced it would acquire Explora BioLabs.
In January 2023, the business announced it would acquire SAMDI Tech, Inc.
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
settoreHealthcare
industriaLife Sciences Tools & Services
dipendenti18.300
paeseUS
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi$4.02B2016-12-31 → 2025-12-27
EPS$-2.912016-12-31 → 2025-12-27
Flusso di cassa libero$518M2016-12-31 → 2025-12-27
Margine netto-6.0%2016-12-31 → 2025-12-27
Valutazione e Rapporti
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
| Metrica | Tendenza 5 anni | CRL | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| P/E (TTM) | -60.5media 5 anni ≈191.6 | ≈191.6 | · | · | |
| P/S (TTM) | 3.5media 5 anni ≈3.2 | ≈3.2 | 4.9 | Sottovalutato | |
| P/B (MRQ) | 4.9media 5 anni ≈4.1 | ≈4.1 | 3.6 | Valore equo | |
| EV / EBITDA | 32.8media 5 anni ≈16.9 | ≈16.9 | 25.4 | Sottovalutato | |
| Prezzo / FCF (TTM) | 37.4media 5 anni ≈28.8 | ≈28.8 | · | · | |
| Prezzo / Flusso di cassa (TTM) | 23.8media 5 anni ≈17.3 | ≈17.3 | 26.2 | Sottovalutato | |
| EV / Revenue (EV / Ricavi) | 3.5media 5 anni ≈3.1 | ≈3.1 | · | · | |
| EV / FCF | 27.1media 5 anni ≈28.3 | ≈28.3 | · | · | |
| Prezzo / Valore contabile tangibile (MRQ) | 5.4 | · | · | · |
La mediana dei peer viene calcolata su base standardizzata per metrica e potrebbe non corrispondere sempre alla base TTM/MRQ mostrata per questo titolo.
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
| Metrica | Tendenza 5 anni | CRL | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Margine Operativo (TTM) | 2.3%media 5 anni ≈10.8% | ≈10.8% | 12.1% | In linea | |
| Margine EBITDA (TTM) | 9.7%media 5 anni ≈19.2% | ≈19.2% | 14.8% | Di prim'ordine | |
| Pretax Margin (Margine ante imposte) | -2.5%media 5 anni ≈8.6% | ≈8.6% | 12.4% | Debole | |
| Margine di Profitto Netto (TTM) | -6.0%media 5 anni ≈6.3% | ≈6.3% | 10.8% | Debole | |
| ROA (TTM) | -3.2%media 5 anni ≈3.4% | ≈3.4% | 2.0% | Debole | |
| ROE (TTM) | -7.7%media 5 anni ≈9.0% | ≈9.0% | 3.3% | Debole | |
| ROIC | 1.1%media 5 anni ≈10.7% | ≈10.7% | 3.0% | Debole |
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
| Metrica | Tendenza 5 anni | CRL | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto (MRQ) | 0.0media 5 anni ≈0.0 | ≈0.0 | 0.1 | Basso indebitamento | |
| Rapporto corrente (MRQ) | 1.3media 5 anni ≈1.4 | ≈1.4 | 1.8 | Bassa liquidità | |
| Quick Ratio | 0.8media 5 anni ≈0.9 | ≈0.9 | 1.2 | Bassa liquidità |
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
| Metrica | Tendenza 5 anni | CRL | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Revenue YoY (Ricavi YoY) | -0.85%media 5 anni ≈6.9% | ≈6.9% | · | · | |
| Revenue CAGR 3Y (CAGR Ricavi 3Y) | 0.33%media 5 anni ≈5.7% | ≈5.7% | · | · | |
| Revenue CAGR 5Y (CAGR Ricavi 5Y) | 6.6% | · | · | · | |
| EPS YoY | -97.8%media 5 anni ≈-17.6% | ≈-17.6% | · | · | |
| Net Income YoY (Utile Netto YoY) | -95.3%media 5 anni ≈-16.5% | ≈-16.5% | · | · | |
| EPS CAGR 3Y (CAGR EPS 3 anni) | -70.3% | · | · | · | |
| Net Income CAGR 3Y (CAGR Utile Netto 3 anni) | -61.6% | · | · | · |
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
| Metrica | Tendenza 5 anni | CRL | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Asset Turnover (Rotazione delle attività) | 0.5media 5 anni ≈0.5 | ≈0.5 | 0.5 | In linea | |
| Receivables Turnover (Rotazione dei crediti) | 5.6media 5 anni ≈5.5 | ≈5.5 | 5.6 | In linea | |
| Revenue / Employee (Ricavi / Dipendente) | ≈$219.4K | · | · | · |
valore · ≈ media 5 anni · mediana del settore · giudizio rispetto alla mediana
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
8.9%
Prossimo report
Nov 03, 2026
| Periodo | Rapporto | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|---|
| 30 Giugno 2026 | Ago 12, 2026 | $3.02 | $2.76 | 9.2% |
| 31 Marzo 2026 | $2.06 | $1.96 | 5.0% | |
| 31 Dicembre 2025 | $2.39 | $2.37 | 0.98% | |
| 30 Settembre 2025 | $2.43 | $2.36 | 2.9% | |
| 30 Giugno 2025 | $3.12 | $2.52 | 23.7% | |
| 31 Marzo 2025 | $2.34 | $2.10 | 11.4% |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Cost of Revenue | · | · | · | · | · | · | · | · | $290M | $277M | $264M | $266M | |
| SG&A Expense | $743M | $751M | $748M | $665M | $620M | $529M | $518M | $444M | $371M | $365M | $300M | $269M | |
| Operating Income | $25M | $227M | $617M | $651M | $590M | $433M | $351M | $331M | $288M | $238M | $206M | $178M | |
| Interest Expense | · | · | $137M | $59M | $74M | $86M | $61M | $64M | $30M | $28M | $15M | $12M | |
| Interest Income | $5M | $9M | $5M | $780.0K | $652.0K | $834.0K | $2M | $812.0K | $690.0K | $1M | $1M | $1M | |
| Other Non-op | $-23M | $-17M | $96M | $31M | $-36M | $100M | $12M | $13M | $38M | $12M | $3M | $11M | |
| Pretax Income | $-100M | $93M | $581M | $623M | $481M | $447M | $304M | $282M | $297M | $223M | $195M | $178M | |
| Income Tax | $43M | $68M | $101M | $130M | $82M | $82M | $50M | $54M | $171M | $67M | $43M | $48M | |
| Net Income | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| EPS (Basic) | $-2.91 | $0.20 | $9.27 | $9.57 | $7.77 | $7.35 | $5.17 | $4.72 | $2.60 | $3.29 | $3.21 | $2.72 | |
| EPS (Diluted) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 | $3.13 | $2.66 | |
| Shares (Basic) | 49,564,000 | 51,380,000 | 51,227,000 | 50,812,000 | 50,293,000 | 49,550,000 | 48,730,000 | 47,947,000 | 47,481,000 | 47,014,000 | 46,496,000 | 46,627,000 | |
| Shares (Diluted) | 49,564,000 | 51,628,000 | 51,451,000 | 51,301,000 | 51,425,000 | 50,611,000 | 49,693,000 | 49,018,000 | 48,564,000 | 47,958,000 | 47,634,000 | 47,558,000 | |
| EBITDA | $428M | $589M | $931M | $955M | $855M | $668M | $549M | $493M | $419M | $364M | $301M | $274M |
Stato Patrimoniale
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $214M | $195M | $277M | $234M | $241M | $228M | $238M | $195M | $164M | $118M | $118M | $160M | |
| Short-term Investments | · | · | · | · | $1M | $1M | $941.0K | $885.0K | $28M | $4M | $21M | · | |
| Receivables | $709M | $721M | $780M | $752M | $643M | $618M | $514M | $472M | $430M | $364M | $270M | $258M | |
| Inventory | $299M | $279M | $380M | $256M | $199M | $186M | $161M | $128M | $115M | $96M | $94M | $89M | |
| Prepaid Expense | $129M | $106M | $83M | $108M | $97M | $73M | $56M | $49M | $81M | $45M | $47M | $45M | |
| Other Current Assets | · | · | · | · | · | $0 | $300.0K | $300.0K | $0 | $45M | $47M | $73M | |
| Current Assets | $1.45B | $1.40B | $1.61B | $1.44B | $1.27B | $1.20B | $1.02B | $898M | $827M | $657M | $559M | $579M | |
| PP&E (Net) | $1.66B | $1.60B | $1.64B | $1.47B | $1.29B | $1.12B | $1.04B | $933M | $782M | $756M | $678M | $677M | |
| PP&E (Gross) | $3.19B | $3.06B | $2.98B | $2.63B | $2.39B | $2.21B | $2.02B | $1.81B | $1.58B | $1.46B | $1.32B | $1.33B | |
| Accum. Depreciation | $1.54B | $1.45B | $1.34B | $1.16B | $1.10B | $1.09B | $978M | $874M | $801M | $706M | $645M | $655M | |
| Goodwill | $2.76B | $2.85B | $3.10B | $2.85B | $2.71B | $1.81B | $1.54B | $1.25B | $805M | $788M | $439M | $321M | |
| Intangibles | $340M | $723M | $864M | $955M | $1.06B | $788M | $689M | $611M | $370M | $394M | $281M | $281M | |
| Other Non-current Assets | $293M | $278M | $309M | $148M | $152M | $353M | $213M | $144M | $124M | $88M | $72M | $73M | |
| Total Assets | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Accounts Payable | $149M | $140M | $169M | $206M | $198M | $122M | $111M | $66M | $78M | $68M | $37M | $34M | |
| Accrued Liabilities | $270M | $232M | $228M | $220M | $229M | $150M | $139M | $107M | $90M | $84M | $89M | $67M | |
| Current Liabilities | $1.12B | $994M | $1.06B | $1.09B | $1.03B | $840M | $710M | $558M | $464M | $430M | $312M | $295M | |
| Capital Leases | $434M | $484M | $419M | $390M | $253M | $156M | $116M | · | · | · | · | · | |
| Deferred Tax | $95M | $107M | $191M | $216M | $240M | $217M | $167M | $144M | $90M | $56M | $48M | $23M | |
| Other Non-current Liabilities | $138M | $195M | $223M | $175M | $243M | $205M | $183M | $179M | $195M | $159M | $89M | $100M | |
| Total Liabilities | $3.92B | $4.02B | $4.54B | $4.58B | $4.43B | $3.35B | $3.03B | $2.52B | $1.87B | $1.86B | $1.30B | $1.17B | |
| Long-term Debt | · | · | · | · | · | · | · | $1.61B | $1.09B | $1.18B | $814M | $717M | |
| Total Debt | $166.0K | $155.0K | $3M | $1M | $101.0K | $47M | $36M | $1.65B | $1.12B | $1.21B | $836M | $754M | |
| Common Stock | $492.0K | $511.0K | $513.0K | $509.0K | $505.0K | $498.0K | $489.0K | $482.0K | $875.0K | $863.0K | $855.0K | $845.0K | |
| Retained Earnings | $1.39B | $1.81B | $1.89B | $1.43B | $981M | $625M | $280M | $42M | $289M | $165M | $11M | $-139M | |
| Treasury Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $55.0K | $1.66B | $1.55B | $1.54B | $1.42B | |
| AOCI | $-172M | $-317M | $-196M | $-262M | $-165M | $-139M | $-178M | $-173M | $-145M | $-254M | $-136M | $-74M | |
| Stockholders' Equity | $3.16B | $3.46B | $3.60B | $2.98B | $2.53B | $2.11B | $1.63B | $1.32B | $1.05B | $837M | $733M | $672M | |
| Liabilities + Equity | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Shares Outstanding | 49,217,000 | 51,141,000 | 51,338,000 | 50,944,000 | 50,480,000 | 49,767,000 | 48,936,000 | 48,209,000 | 47,402,000 | 47,363,000 | 46,698,000 | 47,327,000 |
Flusso di cassa
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $403M | $362M | $314M | $304M | $266M | $235M | $198M | $162M | $131M | $127M | $95M | $96M | |
| Stock-based Comp | $71M | $70M | $72M | $74M | $71M | $56M | $57M | $47M | $44M | $44M | $40M | $31M | |
| Deferred Tax | $-75M | $-67M | $-51M | $-33M | $-20M | $2M | $-21M | $-10M | $28M | $3M | $4M | $9M | |
| Amort. of Intangibles | $179M | $138M | $137M | $147M | $125M | $112M | $90M | $65M | $41M | $42M | $24M | $26M | |
| Restructuring | $100M | $107M | $30M | $8M | $7M | $13M | $14M | $10M | $5M | $18M | $8M | $8M | |
| Other Non-cash | $483M | $348M | $-126M | $-211M | $53M | $-111M | $-5M | $16M | $-8M | $-28M | $-395.0K | · | |
| Operating Cash Flow | $738M | $735M | $684M | $620M | $761M | $547M | $481M | $441M | $318M | $317M | $307M | $252M | |
| CapEx | $219M | $233M | $319M | $325M | $229M | $167M | $141M | $140M | $82M | $55M | $63M | $57M | |
| Investing Cash Flow | $-209M | $-245M | $-563M | $-608M | $-1.44B | $-602M | $-682M | $-955M | $-73M | $-693M | · | · | |
| Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | $237M | $1.04B | · | · | |
| Net Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | · | · | · | · | |
| Stock Repurchased | $361M | $119M | $24M | $39M | $41M | $24M | $18M | $14M | $107M | $12M | $117M | $122M | |
| Net Stock Activity | $-361M | $-119M | $-24M | $-39M | $-41M | $-24M | $-18M | $-14M | $-107M | $-12M | $-117M | $-122M | |
| Financing Cash Flow | $-537M | $-551M | $-86M | $-42M | $673M | $47M | $232M | $558M | $-208M | $381M | · | · | |
| Net Change in Cash | $10M | $-79M | $43M | $-5M | $13M | $-7M | $43M | $31M | $46M | $-69.0K | $-43M | $4M | |
| Taxes Paid | $120M | $126M | $90M | $76M | $75M | $60M | $54M | $68M | · | · | · | · | |
| Free Cash Flow | $518M | $502M | $365M | $295M | $532M | $380M | $340M | $301M | $236M | $245M | $225M | $195M | |
| Levered FCF | · | · | $252M | $248M | $471M | $309M | $290M | $250M | $223M | $226M | $213M | $186M |
Redditività
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% | 14.8% | 13.4% | 14.6% | 15.5% | 14.1% | 15.1% | 13.7% | |
| Net Margin | -3.6% | 0.55% | 11.5% | 12.2% | 11.0% | 12.5% | 9.6% | 10.0% | 6.6% | 9.2% | 10.9% | · | |
| Pretax Margin | -2.5% | 2.3% | 14.1% | 15.7% | 13.6% | 15.3% | 11.6% | 12.4% | 16.0% | 13.3% | 14.3% | 13.7% | |
| EBITDA Margin | 10.7% | 14.5% | 22.6% | 24.0% | 24.2% | 22.8% | 20.9% | 21.8% | 22.5% | 21.6% | 22.1% | 21.1% | |
| ROA | -2.0% | 0.28% | 6.0% | 6.7% | 6.2% | 7.1% | 5.9% | 6.7% | 4.4% | 6.5% | 7.6% | · | |
| ROE | -4.4% | 0.63% | 14.4% | 17.6% | 16.8% | 19.4% | 17.1% | 19.2% | 13.1% | 19.7% | 21.2% | · | |
| ROIC | 1.1% | 1.8% | 14.2% | 17.3% | 19.3% | 16.4% | 17.6% | 9.0% | 5.6% | 8.1% | 10.2% | 9.1% |
Liquidità e Solvibilità
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 | 1.4 | 1.4 | 1.6 | 1.8 | 1.5 | 1.8 | 2.0 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 | 1.0 | 1.1 | 1.2 | 1.3 | 1.1 | 1.2 | 1.4 | |
| Debt / Equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.3 | 1.1 | 1.4 | 1.1 | 1.1 | |
| LT Debt / Equity | · | · | · | · | · | · | · | 1.2 | 1.0 | 1.4 | 1.1 | 1.1 | |
| Interest Coverage | · | · | 4.5 | 11.0 | 8.0 | 5.0 | 5.8 | 5.2 | 9.7 | 8.6 | 13.7 | 14.9 |
Efficienza
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
| Inventory Turnover | · | · | · | · | · | · | · | · | 2.7 | 2.9 | 2.9 | 3.0 | |
| Receivables Turnover | 5.6 | 5.4 | 5.4 | 5.7 | 5.6 | 5.2 | 5.3 | 5.0 | 4.7 | 5.3 | 5.2 | 5.4 |
Per Azione
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $64.30 | $67.69 | $70.06 | $58.42 | $50.21 | $42.49 | $33.40 | $27.33 | $22.05 | $17.67 | $15.70 | $14.20 | |
| Revenue / Share | $81.01 | $78.45 | $80.26 | $77.50 | $68.84 | $57.77 | $52.75 | $46.23 | $38.25 | $35.06 | · | · | |
| Cash Flow / Share | $14.88 | $14.23 | $13.29 | $12.08 | $14.79 | $10.80 | $9.68 | $9.00 | $6.55 | $6.26 | · | · | |
| Cash / Share | $4.34 | $3.81 | $5.39 | $4.59 | $4.78 | $4.59 | $4.86 | $4.05 | $3.46 | $2.48 | $2.53 | $3.38 | |
| EPS (TTM) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 | $3.13 | $2.66 |
Tassi di Crescita
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -0.85% | -1.9% | 3.9% | 12.3% | 21.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 0.33% | 4.6% | 12.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | -97.8% | -2.7% | 24.7% | 5.6% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | -70.3% | 8.6% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | -95.3% | -2.4% | 24.4% | 7.3% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | -61.6% | 9.2% | · | · | · | · | · | · | · | · | · |
Valutazione (TTM)
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Net Income TTM | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| Market Cap | $10.02B | $9.52B | $12.14B | $11.10B | $18.64B | $12.53B | $7.43B | $5.39B | $5.19B | $3.61B | $3.74B | $3.04B | |
| Enterprise Value | $9.81B | $9.33B | $11.86B | $10.87B | $18.40B | $12.34B | $7.23B | $6.84B | $6.12B | $4.70B | $4.46B | $3.64B | |
| P/E | -70.0 | 930.8 | 25.6 | 23.0 | 48.6 | 35.0 | 30.0 | 24.2 | 43.1 | 23.6 | 25.6 | 24.2 | |
| P/S | 2.5 | 2.4 | 2.9 | 2.8 | 5.3 | 4.3 | 2.8 | 2.4 | 2.8 | 2.1 | 2.7 | 2.3 | |
| P/B | 3.2 | 2.8 | 3.4 | 3.7 | 7.4 | 5.9 | 4.5 | 4.1 | 5.0 | 4.3 | 5.1 | 4.5 | |
| P / Tangible Book | 166.0 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | 13.6 | 13.0 | 17.7 | 17.9 | 24.5 | 22.9 | 15.5 | 12.2 | 16.3 | 12.0 | 13.0 | 12.1 | |
| P / FCF | 19.3 | 19.0 | 33.2 | 37.6 | 35.0 | 33.0 | 21.8 | 17.9 | 22.0 | 14.7 | 16.6 | 15.6 | |
| EV / EBITDA | 22.9 | 15.8 | 12.7 | 11.4 | 21.5 | 18.5 | 13.2 | 13.9 | 14.6 | 12.9 | 14.8 | 13.3 | |
| EV / FCF | 18.9 | 18.6 | 32.5 | 36.9 | 34.6 | 32.5 | 21.2 | 22.7 | 26.0 | 19.2 | 19.8 | 18.6 | |
| EV / Revenue | 2.4 | 2.3 | 2.9 | 2.7 | 5.2 | 4.2 | 2.8 | 3.0 | 3.3 | 2.8 | 3.3 | 2.8 | |
| Earnings Yield | -1.4% | 0.11% | 3.9% | 4.3% | 2.1% | 2.9% | 3.3% | 4.1% | 2.3% | 4.2% | 3.9% | 4.1% |
Conto Economico
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.00B | $996M | $994M | $1.00B | $1.03B | $984M | $1.00B | $1.01B | $1.03B | $1.01B | $1.01B | $1.03B | $1.03B | $1.10B | $989M | |
| Cost of Revenue | · | · | · | · | · | · | · | $661M | $672M | $667M | · | $665M | $652M | · | · | |
| SG&A Expense | $229M | $159M | $196M | $178M | $192M | $178M | $196M | $199M | $170M | $186M | $197M | $176M | $175M | $200M | $184M | |
| Operating Income | $120M | $120M | $-283M | $134M | $100M | $75M | $-168M | $117M | $152M | $126M | $133M | $152M | $168M | $164M | $151M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $35M | · | $34M | $34M | · | $11M | |
| Interest Income | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $3M | $2M | $2M | $1M | $806.0K | $343.0K | $122.0K | |
| Other Non-op | $-37M | $-124M | $12M | $-23M | $154.0K | $-12M | $-23M | $3M | $-2M | $6M | $108M | $-6M | $-3M | $116M | $-17M | |
| Income Tax | $54M | $-15M | $-18M | $32M | $19M | $10M | $-3M | $21M | $25M | $25M | $20M | $25M | $27M | $56M | $25M | |
| Net Income | $-1M | $-15M | $-277M | $54M | $52M | $25M | $-214M | $70M | $94M | $73M | $187M | $87M | $103M | $187M | $96M | |
| EPS (Basic) | $-0.03 | $-0.30 | $-5.58 | $1.11 | $1.06 | $0.50 | $-4.20 | $1.34 | $1.75 | $1.31 | $3.65 | $1.70 | $2.02 | $3.68 | $1.90 | |
| EPS (Diluted) | $-0.03 | $-0.30 | $-5.57 | $1.10 | $1.06 | $0.50 | $-4.17 | $1.33 | $1.74 | $1.30 | $3.64 | $1.69 | $2.01 | $3.66 | $1.88 | |
| Shares (Basic) | 48,021,000 | 48,951,000 | · | 49,213,000 | 49,149,000 | 50,677,000 | · | 51,394,000 | 51,551,000 | 51,437,000 | · | 51,283,000 | 51,097,000 | · | 50,870,000 | |
| Shares (Diluted) | 48,021,000 | 48,951,000 | · | 49,426,000 | 49,316,000 | 50,853,000 | · | 51,583,000 | 51,846,000 | 51,842,000 | · | 51,607,000 | 51,428,000 | · | 51,283,000 | |
| EBITDA | $187M | $187M | · | $219M | $220M | $195M | · | $206M | $238M | $211M | · | $230M | $245M | · | $226M |
Stato Patrimoniale
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $192M | $192M | $214M | $207M | $183M | $229M | $195M | $210M | $179M | $327M | · | $157M | $202M | · | $194M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $950.0K | |
| Receivables | $712M | $700M | $709M | $734M | $768M | $757M | $721M | $754M | $762M | $787M | · | $799M | $788M | · | $771M | |
| Inventory | $346M | $360M | $299M | $303M | $280M | $290M | $279M | $336M | $349M | $361M | · | $293M | $263M | · | $262M | |
| Prepaid Expense | $179M | $135M | $129M | $166M | $130M | $100M | $106M | $102M | $111M | $99M | · | $93M | $92M | · | $97M | |
| Current Assets | $1.53B | $1.49B | $1.45B | $1.53B | $1.47B | $1.51B | $1.40B | $1.49B | $1.50B | $1.67B | · | $1.44B | $1.45B | · | $1.42B | |
| PP&E (Net) | $1.49B | $1.51B | $1.66B | $1.59B | $1.61B | $1.59B | $1.60B | · | · | · | · | · | · | · | · | |
| PP&E (Gross) | $2.96B | $2.94B | $3.19B | $3.09B | $3.10B | $3.05B | $3.06B | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $1.46B | $1.43B | $1.54B | $1.50B | $1.50B | $1.46B | $1.45B | · | · | · | · | · | · | · | · | |
| Goodwill | $3.08B | $3.04B | $2.76B | $2.92B | $2.94B | $2.87B | $2.85B | $3.12B | $3.08B | $3.07B | · | $2.88B | $2.90B | · | $2.78B | |
| Intangibles | $253M | $249M | $340M | $571M | $602M | $656M | $723M | $778M | $800M | $828M | · | $886M | $958M | · | $968M | |
| Other Non-current Assets | $588M | $826M | $293M | $291M | $296M | $294M | $278M | $307M | $301M | $303M | · | $155M | $154M | · | $430M | |
| Total Assets | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Accounts Payable | $141M | $134M | $149M | $170M | $146M | $149M | $140M | $136M | $133M | $130M | · | $136M | $120M | · | $182M | |
| Accrued Liabilities | $380M | $372M | $270M | $229M | $232M | $242M | $232M | $208M | $192M | $191M | · | $198M | $221M | · | $197M | |
| Current Liabilities | $1.13B | $1.09B | $1.12B | $1.12B | $1.08B | $1.05B | $994M | $1.01B | $948M | $955M | · | $994M | $981M | · | $1.01B | |
| Capital Leases | $408M | $393M | $434M | $443M | $454M | $475M | $484M | $433M | $429M | $418M | · | $390M | $418M | · | $369M | |
| Deferred Tax | $79M | $81M | $95M | $123M | $109M | $107M | $107M | $168M | $165M | $180M | · | $185M | $212M | · | $196M | |
| Other Non-current Liabilities | $403M | $511M | $138M | $189M | $185M | $196M | $195M | $237M | $225M | $235M | · | $173M | $187M | · | $195M | |
| Total Liabilities | $4.64B | $4.74B | $3.92B | $4.06B | $4.16B | $4.34B | $4.02B | $4.18B | $4.18B | $4.45B | · | $4.26B | $4.54B | · | $4.71B | |
| Total Debt | $5M | $7M | · | $54.0K | $98.0K | $121.0K | · | $157.0K | $435.0K | $459.0K | · | $797.0K | · | · | $0 | |
| Common Stock | $496.0K | $493.0K | $492.0K | $514.0K | $513.0K | $512.0K | $511.0K | $517.0K | $517.0K | $515.0K | · | $514.0K | $512.0K | · | $510.0K | |
| Retained Earnings | $1.37B | $1.37B | $1.39B | $1.94B | $1.89B | $1.84B | $1.81B | $2.12B | $2.05B | $1.96B | · | $1.72B | $1.54B | · | $1.28B | |
| Treasury Stock | $323M | $210M | $0 | $363M | $363M | $357M | $0 | $120M | $18M | $9M | · | $24M | $19M | · | $38M | |
| AOCI | $-196M | $-191M | $-172M | $-192M | $-166M | $-265M | $-317M | $-193M | $-270M | $-250M | · | $-268M | $-239M | · | $-396M | |
| Stockholders' Equity | $2.84B | $2.94B | $3.16B | $3.41B | $3.35B | $3.19B | $3.46B | $3.78B | $3.72B | $3.64B | · | $3.31B | $3.11B | · | $2.63B | |
| Liabilities + Equity | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Shares Outstanding | 47,728,000 | 48,167,000 | 49,217,000 | 49,215,000 | 49,209,000 | 49,115,000 | 51,141,000 | 51,134,000 | 51,613,000 | 51,510,000 | · | 51,296,000 | 51,182,000 | 50,944,000 | 50,877,000 |
Flusso di cassa
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $67M | $67M | $78M | $85M | $120M | $120M | $102M | $88M | $86M | $85M | $81M | $79M | $77M | $78M | $75M | |
| Stock-based Comp | $20M | $22M | $18M | $23M | $17M | $13M | $17M | $19M | $17M | $17M | $20M | $23M | $13M | $22M | $22M | |
| Amort. of Intangibles | $15M | $15M | $21M | $27M | $65M | $65M | $41M | $32M | $32M | $33M | $34M | $34M | $35M | $35M | $36M | |
| Restructuring | $23M | $32M | $26M | $17M | $32M | $24M | $41M | $31M | $18M | $17M | $8M | $15M | $3M | $4M | $1M | |
| Other Non-cash | · | $-34M | · | · | · | $13M | · | · | · | $-45M | · | · | $-84M | · | · | |
| Operating Cash Flow | $180M | $41M | $148M | $214M | $205M | $172M | $159M | $252M | $194M | $130M | $221M | $205M | $109M | $235M | $133M | |
| CapEx | $31M | $56M | $89M | $36M | $35M | $59M | $76M | $39M | $39M | $79M | $78M | $66M | $107M | $89M | $72M | |
| Investing Cash Flow | $28M | $-408M | $-93M | $-34M | $-37M | $-45M | $-76M | $-21M | $-62M | $-86M | $-238M | $-80M | $-169M | $44M | $-92M | |
| Debt Issued | $353M | $912M | $157M | $107M | $547M | $416M | $105M | $236M | $440M | $301M | $443M | $51M | $192M | $154M | $618M | |
| Net Debt Issued | · | $912M | · | · | · | $416M | · | · | · | $301M | · | · | $192M | · | · | |
| Stock Repurchased | $116M | $208M | $96.0K | $93.0K | $7M | $353M | $124.0K | $101M | $9M | $9M | $139.0K | $38.0K | $19M | $159.0K | $24.0K | |
| Net Stock Activity | · | $-208M | · | · | · | $-353M | · | · | · | $-9M | · | · | $-19M | · | · | |
| Financing Cash Flow | $-165M | $348M | $-52M | $-153M | $-227M | $-105M | $-76M | $-208M | $-286M | $18M | $124M | $-163M | $25M | $-249M | $-52M | |
| Net Change in Cash | $42M | $-18M | $7M | $24M | $-47M | $26M | $-6M | $31M | $-158M | $54M | $119M | $-43M | $-32M | $45M | $-11M | |
| Taxes Paid | $16M | $2M | $27M | $19M | $57M | $17M | $31M | $23M | $53M | $19M | $15M | $14M | $14M | · | · | |
| Free Cash Flow | · | $-15M | · | · | · | $112M | · | · | · | $51M | · | · | $3M | · | · |
Redditività
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.9% | 12.0% | · | 13.3% | 9.7% | 7.6% | · | 11.6% | 14.8% | 12.4% | · | 14.8% | 16.3% | · | 15.3% | |
| Net Margin | -0.15% | -1.5% | · | 5.4% | 5.1% | 2.6% | · | 6.9% | 9.2% | 7.2% | · | 8.5% | 10.0% | · | 9.8% | |
| EBITDA Margin | 18.6% | 18.8% | · | 21.8% | 21.3% | 19.8% | · | 20.4% | 23.2% | 20.9% | · | 22.4% | 23.8% | · | 22.8% | |
| ROA | -0.02% | -0.19% | · | 0.70% | 0.67% | 0.32% | · | 0.89% | 1.2% | 0.92% | · | 1.2% | · | · | 1.3% | |
| ROE | -0.05% | -0.48% | · | 1.5% | 1.5% | 0.75% | · | 2.0% | 2.7% | 2.2% | · | 2.9% | · | · | 3.8% |
Liquidità e Solvibilità
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | · | 1.4 | 1.4 | 1.4 | · | 1.5 | 1.6 | 1.7 | · | 1.5 | · | · | 1.4 | |
| Quick Ratio | 0.8 | 0.8 | · | 0.8 | 0.9 | 0.9 | · | 1.0 | 1.0 | 1.2 | · | 1.0 | · | · | 1.0 | |
| Debt / Equity | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · | 0.0 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 3.6 | · | 4.5 | 4.9 | · | 13.3 |
Efficienza
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | · | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | · | 2.1 | 2.1 | 2.1 | · | · | · | · | · | |
| Receivables Turnover | 1.4 | 1.4 | · | 1.4 | 1.3 | 1.3 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | · | · | 1.4 |
Per Azione
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $59.50 | $61.05 | · | $69.20 | $68.14 | $65.04 | · | $73.97 | $72.13 | $70.67 | · | $64.45 | · | · | $51.63 | |
| Revenue / Share | $20.91 | $20.34 | · | $20.33 | $20.93 | $19.35 | · | $19.58 | $19.79 | $19.51 | · | $19.89 | $20.02 | · | $19.29 | |
| Cash Flow / Share | · | $0.84 | · | · | · | $3.38 | · | · | · | $2.51 | · | · | $2.13 | · | · | |
| Cash / Share | $4.02 | $3.98 | · | $4.21 | $3.72 | $4.67 | · | $4.11 | $3.47 | $6.35 | · | $3.06 | · | · | $3.81 | |
| EPS (TTM) | $-4.80 | $-3.71 | · | $-1.51 | $-1.28 | $-0.60 | · | $8.01 | $8.37 | $8.52 | · | $9.25 | $9.68 | · | $8.49 |
Valutazione (TTM)
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.00B | $4.03B | · | $4.02B | $4.03B | $4.02B | · | $4.06B | $4.08B | $4.11B | · | $4.22B | $4.09B | · | $3.78B | |
| Net Income TTM | $-238M | $-185M | · | $-82M | $-67M | $-25M | · | $424M | $442M | $444M | · | $475M | $496M | · | $436M | |
| Market Cap | $10.30B | $7.67B | · | $7.31B | $7.38B | $7.64B | · | $10.14B | $10.66B | $13.96B | · | $10.05B | · | · | $9.54B | |
| Enterprise Value | $10.11B | $7.48B | · | $7.10B | $7.20B | $7.41B | · | $9.93B | $10.48B | $13.63B | · | $9.90B | · | · | $9.35B | |
| P/E | -44.9 | -42.9 | · | -98.4 | -117.2 | -259.2 | · | 24.8 | 24.7 | 31.8 | · | 21.2 | 20.8 | · | 22.1 | |
| P/S | 2.6 | 1.9 | · | 1.8 | 1.8 | 1.9 | · | 2.5 | 2.6 | 3.4 | · | 2.4 | 2.5 | · | 2.5 | |
| P/B | 3.6 | 2.6 | · | 2.1 | 2.2 | 2.4 | · | 2.7 | 2.9 | 3.8 | · | 3.0 | · | · | 3.6 | |
| P / Cash Flow | · | 186.6 | · | · | · | 44.5 | · | · | · | 107.5 | · | · | · | · | · | |
| EV / Revenue | 2.5 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.4 | 2.6 | 3.3 | · | 2.3 | 2.5 | · | 2.5 | |
| Earnings Yield | -2.2% | -2.3% | · | -1.0% | -0.85% | -0.39% | · | 4.0% | 4.0% | 3.1% | · | 4.7% | 4.8% | · | 4.5% |
Periodo più recente a sinistra · valori nulli mostrati come ·
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
| Metrica | 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 |
|---|---|---|---|---|---|
| Ricavi | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B |
| Margine Operativo % | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% |
| Utile netto | $-144M | $22M | $475M | $486M | $391M |
| EPS Diluito | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 |
| Metrica | 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Rapporto corrente | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 |
| Metrica | 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 |
|---|---|---|---|---|---|
| Flusso di cassa libero | $518M | $502M | $365M | $295M | $532M |
Proprietari istituzionali (13F) 607 filer · $13.6B totale · Aggiornato al 30 Settembre 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Detentori
607
Valore detenuto
$13.6B
Nuove posizioni
74
Posizioni chiuse
62
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 74 (-17 vs trimestre precedente) | 62 (-19 vs trimestre precedente) | 193 (0 vs trimestre precedente) | 204 (+13 vs trimestre precedente) | +2.8M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| VANGUARD GROUP INC | $1.174.373.670 | 5.887.175 | 8,65% | Azioni |
| FMR LLC | $961.533.236 | 4.239.752 | 7,09% | Azioni |
| BlackRock, Inc. | $861.475.349 | 3.798.560 | 6,35% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $714.227.026 | 3.149.288 | 5,26% | Azioni |
| Invesco Ltd. | $676.919.391 | 2.984.785 | 4,99% | Azioni |
| HARRIS ASSOCIATES L P | $508.269.048 | 2.241.144 | 3,75% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $501.427.927 | 2.210.979 | 3,70% | Azioni |
| Allspring Global Investments Holdings, LLC | $436.473.035 | 1.905.247 | 3,22% | Azioni |
| STATE STREET CORP | $422.800.968 | 1.864.284 | 3,12% | Azioni |
| DIMENSIONAL FUND ADVISORS LP | $373.848.597 | 1.648.450 | 2,76% | Azioni |
| ARIEL INVESTMENTS, LLC | $341.587.697 | 1.506.185 | 2,52% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $295.598.099 | 1.305.738 | 2,18% | Azioni |
| WELLINGTON MANAGEMENT GROUP LLP | $292.210.525 | 1.288.463 | 2,15% | Azioni |
| CITADEL ADVISORS LLC | $270.696.771 | 1.193.601 | 1,99% | Azioni |
| BANK OF AMERICA CORP /DE/ | $265.930.779 | 1.172.586 | 1,96% | Azioni |
| EARNEST PARTNERS LLC | $254.007.295 | 1.120.011 | 1,87% | Azioni |
| AMERIPRISE FINANCIAL INC | $199.834.979 | 881.189 | 1,47% | Azioni |
| NEUBERGER BERMAN GROUP LLC | $195.633.630 | 862.704 | 1,44% | Azioni |
| SEI INVESTMENTS CO | $184.499.540 | 813.530 | 1,36% | Azioni |
| MORGAN STANLEY | $181.542.851 | 800.487 | 1,34% | Azioni |
| Clearbridge Investments, LLC | $177.185.527 | 781.276 | 1,31% | Azioni |
| COOKE & BIELER LP | $171.369.328 | 755.630 | 1,26% | Azioni |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $157.642.604 | 682.173 | 1,16% | Azioni |
| VICTORY CAPITAL MANAGEMENT INC | $150.762.735 | 664.768 | 1,11% | Azioni |
| UBS Group AG | $146.675.752 | 646.747 | 1,08% | Azioni |
| GOLDMAN SACHS GROUP INC | $145.100.822 | 639.803 | 1,07% | Azioni |
| MILLENNIUM MANAGEMENT LLC | $110.324.717 | 486.462 | 0,81% | Azioni |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $106.061.291 | 467.663 | 0,78% | Azioni |
| BANK OF MONTREAL /CAN/ | $104.270.783 | 459.768 | 0,77% | Azioni |
| NORTHERN TRUST CORP | $101.169.205 | 446.092 | 0,75% | Azioni |
| Gotham Asset Management, LLC | $98.233.181 | 433.146 | 0,72% | Azioni |
| Amundi | $93.528.650 | 412.402 | 0,69% | Azioni |
| NORGES BANK | $83.921.372 | 370.040 | 0,62% | Azioni |
| MARSHALL WACE, LLP | $77.787.835 | 342.995 | 0,57% | Azioni |
| Iron Triangle Partners LP | $75.748.141 | 379.728 | 0,56% | Azioni |
| CITIGROUP INC | $71.714.853 | 316.217 | 0,53% | Azioni |
| BNP PARIBAS FINANCIAL MARKETS | $69.108.583 | 304.725 | 0,51% | Azioni |
| Bank of New York Mellon Corp | $69.054.385 | 304.486 | 0,51% | Azioni |
| Boston Trust Walden Corp | $65.523.486 | 288.917 | 0,48% | Azioni |
| JPMORGAN CHASE & CO | $65.085.033 | 286.317 | 0,48% | Azioni |
| ALLIANCEBERNSTEIN L.P. | $64.615.913 | 374.585 | 0,48% | Azioni |
| SNYDER CAPITAL MANAGEMENT L P | $63.899.443 | 281.756 | 0,47% | Azioni |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $63.174.169 | 278.558 | 0,47% | Azioni |
| DEUTSCHE BANK AG\ | $62.723.084 | 276.569 | 0,46% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $61.384.115 | 270.665 | 0,45% | Azioni |
| PRIMECAP MANAGEMENT CO/CA/ | $60.523.448 | 266.870 | 0,45% | Azioni |
| RAYMOND JAMES FINANCIAL INC | $58.234.910 | 256.779 | 0,43% | Azioni |
| Meridiem Capital Partners LP | $56.012.367 | 246.979 | 0,41% | Azioni |
| Alyeska Investment Group, L.P. | $53.295.650 | 235.000 | 0,39% | Azioni |
| LOOMIS SAYLES & CO L P | $50.725.593 | 223.668 | 0,37% | Azioni |
Attivisti e proprietari del 5%+ 6 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| JANA PARTNERS LLC ×4 depositi | 04 Agosto 2011 | · | Deposito iniziale | · | SEC |
| Relational Investors, LLC, Relational Investors Mid-Cap Fund I, L.P., Relational Investors Mid-Cap Fund II, L.P., Ralph V. Whitworth, David H. Batchelder, California State Teachers’ Retirement System ×3 depositi | 09 Febbraio 2011 | · | Deposito iniziale | · | SEC |
| Neuberger Berman Group LLC, Neuberger Berman LLC, Neuberger Berman Management ×3 depositi | 07 Dicembre 2010 | · | Deposito iniziale | · | SEC |
| Persona segnalante non divulgata | 16 Giugno 2010 | · | Deposito iniziale | · | SEC |
| Persona segnalante non divulgata | 07 Giugno 2010 | · | Deposito iniziale | Investimento passivo | SEC |
| Charles River Laboratories International, Inc. IRS No. 061397316 | 05 Maggio 2010 | · | Deposito iniziale | Campagna per il consiglio di amministrazione | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insider aziendali 57 insider · 23 dirigenti · 29 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Birgit Girshick | Chief Executive Officer | 19 Agosto 2026 G | 35.485 | 0 | 1 | $-1.819.350 |
| Glenn Coleman | EVP & Chief Financial Officer | 30 Settembre 2026 P | 27.762 | 1 | 0 | $2.974 |
| Flavia Pease | Corporate Executive VP & CFO | 31 Maggio 2025 F | 17.297 | 0 | 0 | $0 |
| David Ross Smith | Corporate Executive VP & CFO | 03 Marzo 2022 M | 25.819 | 0 | 0 | $0 |
| Davide Molho | President & COO | 24 Luglio 2018 M | 17.155 | 0 | 0 | $0 |
| Shannon M Parisotto | CEVP, Disc & Safety Assessment | 19 Agosto 2026 M | 4.807 | 0 | 3 | $-2.965.466 |
| Mark Mintz | EVP, Chief Information Officer | 31 Maggio 2026 F | 9.546 | 0 | 0 | $0 |
| William D Barbo | Corporate Executive VP & CCO | 07 Novembre 2024 G | 23.337 | 0 | 0 | $0 |
| John W Kuo | CEVP General Counsel & CCO | 01 Giugno 2020 A | 3.171 | 0 | 0 | $0 |
| David P Johst | Corporate Executive VP | 29 Maggio 2020 A | 224.478 | 0 | 0 | $0 |
| John J Crowley | SVP, Chief Accounting Officer | 01 Ottobre 2016 F | 5.599 | 0 | 0 | $0 |
| Nancy Gillett | Corporate Executive VP | 02 Marzo 2016 S | 11.034 | 0 | 0 | $0 |
| Jorg Geller | Corporate Executive VP | 25 Febbraio 2015 M | 14.094 | 0 | 0 | $0 |
| RENAUD REAL H | Corp. Executive VP | 11 Agosto 2010 F | 74.390 | 0 | 0 | $0 |
| Christopher Berthoux | Executive Vice President | 26 Febbraio 2010 A | 31.897 | 0 | 0 | $0 |
| Joanne P Acford | Corp. Sr VP, GC and Corp. Sec | 11 Agosto 2007 F | 37.109 | 0 | 0 | $0 |
| David J Elliott | Officer | 29 Giugno 2007 M | 11.750 | 0 | 0 | $0 |
| Cheri L Walker | Corporate Senior VP | 01 Maggio 2007 A | 6.262 | 0 | 0 | $0 |
| Stephanie B Wells | Senior Vice President | 02 Aprile 2007 A | 11.500 | 0 | 0 | $0 |
| Nicholas Ventresca | Senior Vice President | 02 Aprile 2007 F | 12.713 | 0 | 0 | $0 |
| John C Ho | Senior Vice President | 23 Febbraio 2007 A | 12.710 | 0 | 0 | $0 |
| Brian Bathgate | Corporate Vice President | 27 Febbraio 2006 S | 16.134 | 0 | 0 | $0 |
| Alastair Stuart Mcewan | Corporate VP | 23 Dicembre 2004 M | 8.000 | 0 | 0 | $0 |
| James C Foster | Direttore | 25 Agosto 2026 M | 31.596 | 0 | 3 | $-34.844.875 |
| Nancy C Andrews | Direttore | 18 Agosto 2026 M | 1.438 | 0 | 1 | $-163.443 |
| Steven Barg | Direttore | 02 Giugno 2026 A | 3.287 | 0 | 0 | $0 |
| Reshema Kemps-Polanco | Direttore | 08 Maggio 2026 A | 4.563 | 0 | 0 | $0 |
| George Llado | Direttore | 08 Maggio 2026 A | 6.702 | 0 | 0 | $0 |
| Abraham Ceesay | Direttore | 08 Maggio 2026 A | 2.384 | 0 | 0 | $0 |
| Mark J Enyedy | Direttore | 08 Maggio 2026 A | 2.384 | 0 | 0 | $0 |
| Paul W Graves | Direttore | 08 Maggio 2026 A | 2.384 | 0 | 0 | $0 |
| Craig B. Thompson | Direttore | 08 Maggio 2026 A | 3.851 | 0 | 0 | $0 |
| Martin Mackay | Direttore | 08 Maggio 2026 A | 17.137 | 0 | 0 | $0 |
| Virginia M Wilson | Direttore | 08 Maggio 2026 A | 6.349 | 0 | 0 | $0 |
| George Massaro | Direttore | 15 Maggio 2025 S | 5.575 | 0 | 0 | $0 |
| Richard F Wallman | Direttore | 07 Novembre 2024 S | 0 | 0 | 0 | $0 |
| Deborah Turner Kochevar | Direttore | 13 Maggio 2024 A | 7.894 | 0 | 0 | $0 |
| Robert J Bertolini | Direttore | 13 Maggio 2024 A | 32.802 | 0 | 0 | $0 |
| Richard C Reese | Direttore | 15 Maggio 2023 A | 65.541 | 0 | 0 | $0 |
| George M Milne JR | Direttore | 07 Maggio 2021 A | 29.079 | 0 | 0 | $0 |
| Stephen D Chubb | Direttore | 23 Febbraio 2021 M | 40.529 | 0 | 0 | $0 |
| Jean-Paul Mangeolle | Direttore | 22 Maggio 2019 A | 3.886 | 0 | 0 | $0 |
| William Waltrip | Direttore | 05 Dicembre 2012 S | 21.830 | 0 | 0 | $0 |
| Samuel O Thier MD | Direttore | 09 Maggio 2012 A | 18.230 | 0 | 0 | $0 |
| Douglas E Rogers | Direttore | 07 Maggio 2010 A | 12.859 | 0 | 0 | $0 |
| Nancy T Chang | Direttore | 07 Maggio 2010 A | 31.010 | 0 | 0 | $0 |
| Linda Mcgoldrick | Direttore | 13 Febbraio 2006 A | · | 0 | 0 | $0 |
| Walter S Nimmo | Direttore | 25 Febbraio 2005 S | 149.447 | 0 | 0 | $0 |
| John Urquhart | Direttore | 17 Febbraio 2005 A | 11.738 | 0 | 0 | $0 |
| Louise S Mccrary | Direttore | 17 Febbraio 2005 A | · | 0 | 0 | $0 |
| Robert Cawthorn | Direttore | 02 Giugno 2004 G | 278.600 | 0 | 0 | $0 |
| Joseph W Laplume | · | 10 Agosto 2026 G | 31.041 | 1 | 1 | $-61.124 |
| Victoria L Creamer | · | 06 Agosto 2026 M | 30.051 | 0 | 1 | $-1.083.030 |
| Michael Gunnar Knell | · | 06 Agosto 2026 M | 11.852 | 0 | 9 | $-1.730.250 |
| Thomas F Ackerman | · | 29 Febbraio 2016 F | 111.346 | 0 | 0 | $0 |
| Dennis R Shaughnessy | · | 29 Novembre 2004 G | 35.511 | 0 | 0 | $0 |
| Michael F Ankcorn | · | 04 Novembre 2004 S | 0 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Proprietà ETF Posseduti da 106 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| EPSB · Harbor ETF Trust | 2,15% | 443 NS | 31 Luglio 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,73% | 51.248 SH | 01 Ottobre 2026 | Giornaliero |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,71% | 5.092 NS | 31 Luglio 2026 | N-PORT |
| EPSV · Harbor ETF Trust | 1,59% | 415 NS | 31 Luglio 2026 | N-PORT |
| EPMV · Harbor ETF Trust | 1,44% | 291 NS | 31 Luglio 2026 | N-PORT |
| ALTL · Pacer Funds Trust | 1,09% | 4.303 NS | 31 Luglio 2026 | N-PORT |
| IBB · iShares Trust | 0,96% | 363.741 SH | 11 Settembre 2026 | Giornaliero |
| LSEQ · Harbor ETF Trust | 0,93% | 614 NS | 31 Luglio 2026 | N-PORT |
| HIBL · Direxion Shares ETF Trust | 0,74% | 2.375 NS | 31 Luglio 2026 | N-PORT |
| SPHB · Invesco Exchange-Traded Fund Trust … | 0,69% | 22.191 SH | 01 Ottobre 2026 | Giornaliero |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0,66% | 259 NS | 31 Luglio 2026 | N-PORT |
| PALC · Pacer Funds Trust | 0,61% | 5.509 NS | 31 Luglio 2026 | N-PORT |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,49% | 12.141 NS | 31 Luglio 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0,45% | 6.439 NS | 31 Luglio 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 0,44% | 24.918 SH | 01 Ottobre 2026 | Giornaliero |
| FFSM · FIDELITY COVINGTON TRUST | 0,40% | 25.814 NS | 31 Luglio 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0,34% | 209.615 NS | 31 Luglio 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,28% | 7.783 NS | 31 Luglio 2026 | N-PORT |
| ESML · iShares Trust | 0,24% | 25.082 SH | 11 Settembre 2026 | Giornaliero |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,24% | 20.898 NS | 31 Luglio 2026 | N-PORT |
| FSMD · FIDELITY COVINGTON TRUST | 0,24% | 25.378 NS | 31 Luglio 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,23% | 13.626 NS | 31 Luglio 2026 | N-PORT |
| VBR · VANGUARD INDEX FUNDS | 0,23% | 701.498 SH | 19 Agosto 2026 | Giornaliero |
| DFAS · Dimensional ETF Trust | 0,22% | 147.648 NS | 31 Luglio 2026 | N-PORT |
| RSP · Invesco Exchange-Traded Fund Trust | 0,22% | 702.813 SH | 01 Ottobre 2026 | Giornaliero |
| IYH · iShares Trust | 0,22% | 28.670 SH | 11 Settembre 2026 | Giornaliero |
| SMMD · iShares Trust | 0,19% | 26.152 SH | 11 Settembre 2026 | Giornaliero |
| IXJ · iShares Trust | 0,17% | 25.598 SH | 11 Settembre 2026 | Giornaliero |
| FHLC · FIDELITY COVINGTON TRUST | 0,17% | 23.486 NS | 31 Luglio 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,16% | 148.331 SH | 19 Agosto 2026 | Giornaliero |
| REVS · Columbia ETF Trust I | 0,15% | 2.111 NS | 31 Luglio 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,15% | 3.646 NS | 31 Luglio 2026 | N-PORT |
| WSML · iShares Trust | 0,14% | 6.080 SH | 11 Settembre 2026 | Giornaliero |
| IWS · iShares Trust | 0,13% | 73.404 SH | 11 Settembre 2026 | Giornaliero |
| VB · VANGUARD INDEX FUNDS | 0,13% | 1.102.914 SH | 19 Agosto 2026 | Giornaliero |
| CURE · Direxion Shares ETF Trust | 0,13% | 947 NS | 31 Luglio 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0,12% | 42.976 NS | 31 Luglio 2026 | N-PORT |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,10% | 2.764 SH | 01 Ottobre 2026 | Giornaliero |
| IEUS · iShares Trust | 0,10% | 5.579 SH | 11 Settembre 2026 | Giornaliero |
| IWR · iShares Trust | 0,10% | 200.615 SH | 11 Settembre 2026 | Giornaliero |
| RECS · Columbia ETF Trust I | 0,10% | 23.999 NS | 31 Luglio 2026 | N-PORT |
| XOEF · iShares Trust | 0,07% | 61 SH | 11 Settembre 2026 | Giornaliero |
| DFUV · Dimensional ETF Trust | 0,06% | 41.352 NS | 31 Luglio 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,06% | 1.302 NS | 31 Luglio 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,05% | 106.991 NS | 31 Luglio 2026 | N-PORT |
| IVE · iShares Trust | 0,04% | 79.930 SH | 11 Settembre 2026 | Giornaliero |
| IUSV · iShares Trust | 0,04% | 42.675 SH | 11 Settembre 2026 | Giornaliero |
| SCZ · iShares Trust | 0,04% | 171.786 SH | 11 Settembre 2026 | Giornaliero |
| VSS · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,04% | 174.824 SH | 19 Agosto 2026 | Giornaliero |
| VOOV · VANGUARD ADMIRAL FUNDS | 0,04% | 11.139 SH | 19 Agosto 2026 | Giornaliero |
| DCOR · Dimensional ETF Trust | 0,04% | 5.545 NS | 31 Luglio 2026 | N-PORT |
| IWD · iShares Trust | 0,04% | 108.791 SH | 11 Settembre 2026 | Giornaliero |
| CHRI · Global X Funds | 0,03% | 11 NS | 31 Luglio 2026 | N-PORT |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,03% | 29.579 SH | 19 Agosto 2026 | Giornaliero |
| PRF · Invesco Exchange-Traded Fund Trust | 0,03% | 9.073 SH | 01 Ottobre 2026 | Giornaliero |
| TOPC · iShares Trust | 0,03% | 32 SH | 11 Settembre 2026 | Giornaliero |
| DFSU · Dimensional ETF Trust | 0,02% | 2.431 NS | 31 Luglio 2026 | N-PORT |
| XVV · iShares Trust | 0,02% | 576 SH | 11 Settembre 2026 | Giornaliero |
| QVML · Invesco Exchange-Traded Fund Trust … | 0,02% | 1.252 SH | 01 Ottobre 2026 | Giornaliero |
| PBP · Invesco Exchange-Traded Fund Trust | 0,02% | 287 SH | 30 Settembre 2026 | Giornaliero |
| RWL · Invesco Exchange-Traded Fund Trust … | 0,02% | 7.028 SH | 01 Ottobre 2026 | Giornaliero |
| EGLE · Global X Funds | 0,02% | 2 NS | 31 Luglio 2026 | N-PORT |
| IVV · iShares Trust | 0,02% | 607.129 SH | 11 Settembre 2026 | Giornaliero |
| VOO · VANGUARD INDEX FUNDS | 0,02% | 1.250.774 SH | 19 Agosto 2026 | Giornaliero |
| VTI · VANGUARD INDEX FUNDS | 0,02% | 1.530.468 SH | 19 Agosto 2026 | Giornaliero |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,02% | 8.168 SH | 19 Agosto 2026 | Giornaliero |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,02% | 4.112 SH | 19 Agosto 2026 | Giornaliero |
| ESGV · VANGUARD WORLD FUND | 0,02% | 11.106 SH | 19 Agosto 2026 | Giornaliero |
| IWV · iShares Trust | 0,02% | 14.165 SH | 11 Settembre 2026 | Giornaliero |
| IWB · iShares Trust | 0,02% | 33.863 SH | 11 Settembre 2026 | Giornaliero |
| XRMI · Global X Funds | 0,02% | 41 NS | 31 Luglio 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,02% | 9.979 NS | 31 Luglio 2026 | N-PORT |
| XYLD · Global X Funds | 0,02% | 2.566 NS | 31 Luglio 2026 | N-PORT |
| IYY · iShares Trust | 0,02% | 2.018 SH | 11 Settembre 2026 | Giornaliero |
| ITOT · iShares Trust | 0,02% | 63.582 SH | 11 Settembre 2026 | Giornaliero |
| PHDG · Invesco Actively Managed Exchange-T… | 0,02% | 38 SH | 01 Ottobre 2026 | Giornaliero |
| PTLC · Pacer Funds Trust | 0,02% | 2.492 NS | 31 Luglio 2026 | N-PORT |
| TILT · FlexShares Trust | 0,02% | 1.620 NS | 31 Luglio 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,02% | 14.645 NS | 31 Luglio 2026 | N-PORT |
| XYLG · Global X Funds | 0,02% | 45 NS | 31 Luglio 2026 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0,02% | 182 NS | 31 Luglio 2026 | N-PORT |
| QDPL · Pacer Funds Trust | 0,02% | 1.141 NS | 31 Luglio 2026 | N-PORT |
| XTR · Global X Funds | 0,01% | 3 NS | 31 Luglio 2026 | N-PORT |
| HCMT · Direxion Shares ETF Trust | 0,01% | 332 NS | 31 Luglio 2026 | N-PORT |
| SPXL · Direxion Shares ETF Trust | 0,01% | 3.766 NS | 31 Luglio 2026 | N-PORT |
| IEUR · iShares Trust | 0,01% | 37.473 SH | 11 Settembre 2026 | Giornaliero |
| XCLR · Global X Funds | 0,01% | 2 NS | 31 Luglio 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,01% | 1.973 SH | 01 Ottobre 2026 | Giornaliero |
| VGK · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 110.946 SH | 19 Agosto 2026 | Giornaliero |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 77.796 SH | 19 Agosto 2026 | Giornaliero |
| VEA · VANGUARD TAX-MANAGED FUNDS | 0,01% | 447.656 SH | 19 Agosto 2026 | Giornaliero |
| IDEV · iShares Trust | 0,01% | 52.174 SH | 11 Settembre 2026 | Giornaliero |
| IEFA · iShares Trust | 0,00% | 272.340 SH | 11 Settembre 2026 | Giornaliero |
| NEAR · iShares U.S. ETF Trust | 0,00% | 140.000 SH | 09 Settembre 2026 | Giornaliero |
| DFLV · Dimensional ETF Trust | 0,00% | 377 NS | 31 Luglio 2026 | N-PORT |
| IXUS · iShares Trust | 0,00% | 22.623 SH | 11 Settembre 2026 | Giornaliero |
| VXUS · VANGUARD STAR FUNDS | 0,00% | 664.961 SH | 19 Agosto 2026 | Giornaliero |
| VSGX · VANGUARD WORLD FUND | 0,00% | 8.805 SH | 19 Agosto 2026 | Giornaliero |
| VGHY · VANGUARD FIXED INCOME SECURITIES FU… | · | · | 15 Luglio 2026 | Giornaliero |
| VCRB · VANGUARD MALVERN FUNDS | · | · | 15 Luglio 2026 | Giornaliero |
| VPLS · VANGUARD MALVERN FUNDS | · | · | 15 Luglio 2026 | Giornaliero |
| VSDB · VANGUARD MALVERN FUNDS | · | · | 15 Luglio 2026 | Giornaliero |
| VGMS · VANGUARD MALVERN FUNDS | · | · | 15 Luglio 2026 | Giornaliero |
| ISCB · iShares Trust | · | 2.146 SH | 11 Settembre 2026 | Giornaliero |
| ISCV · iShares Trust | · | 10.576 SH | 11 Settembre 2026 | Giornaliero |
| SMLF · iShares Trust | · | 18.703 SH | 11 Settembre 2026 | Giornaliero |
CRL Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
rating · 23 analisti
COMPRA
Target mediano
$322.00
+11,0%
6 26,1%
Acquisto forte
11 47,8%
Compra
6 26,1%
Mantieni
0 0,0%
Vendi
0 0,0%
Vendita forte
Target Price a 12 Mesi
15 analisti · 2026-10-02Target medio $305.00 +5,1%
Ora
Prezzo attuale $290.19
Basso$145.00
Media$305.00
Alto$357.00
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
Base FY, prezzi alla chiusura dell'ultimo anno fiscale di ciascuna società.
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| CRL | $10.02B | -70.0 | -0.85% | -3.6% | -4.4% | · |
| WST | $19.81B | 40.5 | 6.2% | 16.1% | 16.2% | 35.9% |
| MEDP | $15.93B | 36.8 | 20.0% | 17.8% | 142.9% | · |
| RVTY | $10.86B | 46.7 | 3.7% | 8.5% | 3.3% | · |
| TEM | · | -41.9 | 83.4% | -19.3% | -61.2% | · |
| TEM | · | -41.9 | 83.4% | -19.3% | -61.2% | · |
| TXG | $2.08B | -46.6 | 5.2% | -6.8% | -5.5% | 69.0% |
| TECH | $11.03B | 60.9 | -0.38% | 15.0% | 9.0% | 65.8% |
| RGEN | $9.23B | 190.5 | 16.4% | 6.6% | 2.4% | · |
| AVTR | $7.82B | -14.7 | -3.4% | -8.1% | -8.9% | 32.6% |
| BIO | · | · | · | · | · | · |
Ultime notizie Notizie recenti che menzionano questa società
Bio-Techne supera Charles River Laboratories International al 477° posto
Nasdaq · 3 mesi fa
Charles River Laboratories International Chiamata sugli utili del primo trimestre Highlights
Yahoo Finance · 4 mesi, 3 settimane fa
Titoli del Tesoro USA tokenizzati vicini ai 14 miliardi di dollari mentre Circle e BlackRock guidano la crescita
Yahoo Finance · 5 mesi, 2 settimane fa
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
Scegli le metriche che contano per te: fai clic sul + accanto a qualsiasi riga in Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Fonte: SEC 10-Q depositato Ago 5, 2026